Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14785039 | 0.86 | MAPT (0.47) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL1595262 | 0.85 | MAPT (0.42) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL1594485 | 0.85 | EPHX2 (0.59) | KMT2AALDH1A1IGF1RRAB9ANPC1 | |
| SCHEMBL4069869 | 0.84 | MAPT (0.44) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL1595003 | 0.80 | EPHX2 (0.55) | MAPTKMT2AMEN1HTTNTRK1 | |
| SCHEMBL4118526 | 0.76 | MAPT (0.66) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL1596621 | 0.76 | PANK3 (0.47) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL2569996 | 0.75 | MAPT (0.50) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL2567422 | 0.74 | MAPT (0.40) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL4118525 | 0.74 | EPHX2 (0.58) | MAPTKMT2AMEN1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755964-B1 | SULFONIC ACID SALTS OF HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS ANTI INFECTIVE CURES GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2755964-B1 | SULFONIC ACID SALTS OF HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS ANTI INFECTIVE CURES GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-9133165-B2 | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | AICURIS GMBH & CO. KG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133165-B2 | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | AICURIS GMBH & CO. KG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133165-B2 | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | AICURIS GMBH & CO. KG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140315924-A1 | SULFONIC ACID SALTS OF HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2014-10-23 | — | — | US | disclosed |
| US-20140315924-A1 | SULFONIC ACID SALTS OF HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2014-10-23 | — | — | US | disclosed |
| US-20140315924-A1 | SULFONIC ACID SALTS OF HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2014-10-23 | — | — | US | disclosed |
| WO-2013037812-A1 | SULFONIC ACID SALTS OF HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2013-03-21 | — | — | WO | disclosed |
| US-7919489-B2 | e.g. 4-({[(4-Chloro-2-methylphenyl)amino]carbonyl}amino)-1-(cyclopropylmethyl)-1H-imidazole-2-carboxylic acid; antiviral agents, especially against cytomegaloviruses and other Herpes viridae; side effect reduction; antibiotic resistance | AICURIS GMBH & CO. KG (DE) | 2011-04-05 | — | — | US | disclosed |
| US-7919489-B2 | e.g. 4-({[(4-Chloro-2-methylphenyl)amino]carbonyl}amino)-1-(cyclopropylmethyl)-1H-imidazole-2-carboxylic acid; antiviral agents, especially against cytomegaloviruses and other Herpes viridae; side effect reduction; antibiotic resistance | AICURIS GMBH & CO. KG (DE) | 2011-04-05 | — | — | US | disclosed |
| US-7919489-B2 | e.g. 4-({[(4-Chloro-2-methylphenyl)amino]carbonyl}amino)-1-(cyclopropylmethyl)-1H-imidazole-2-carboxylic acid; antiviral agents, especially against cytomegaloviruses and other Herpes viridae; side effect reduction; antibiotic resistance | AICURIS GMBH & CO. KG (DE) | 2011-04-05 | — | — | US | disclosed |
| EP-1853582-B1 | HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO KG (DE) | 2009-10-21 | — | — | EP | disclosed |
| EP-1853582-B1 | HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO KG (DE) | 2009-10-21 | — | — | EP | disclosed |
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | AICURIS GMBH & CO. KG (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176859-A1 | HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES | TPMT, TYMP, PAICS | MAPT 2179/4885KMT2A 1448/4885MEN1 422/4885 |
| US-20140315924-A1 | SULFONIC ACID SALTS OF HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES | TPMT, MPST, STS | MAPT 830/4885KMT2A 2561/4885MEN1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.